Peak Strength Bio
Research Use Only: For research use only. Not for human consumption. Content is educational and is not medical advice, diagnosis, or treatment.
Peptides / Peptides / Growth Hormone

CJC-1295 No DAC / Ipamorelin

Synergistic Dual-Pathway Growth Hormone Secretagogue Formulation

CJC-1295 No DAC / Ipamorelin

The CJC-1295 No DAC / Ipamorelin blend is a combination of two distinct, complementary growth hormone secretagogues studied for their synergistic ability to provoke pulsatile growth hormone release. By simultaneously targeting GHRH receptors and ghrelin receptors without the prolonged duration of DAC-conjugated variants, this blend is highly valued in preclinical research exploring metabolic acceleration, cellular repair, and physiological homeostasis.

Typical dose
100 mcg - 300 mcg total peptide per administration, 2-3 times daily in fasting states
Half-life
CJC-1295 No DAC: approx. 30 minutes; Ipamorelin: approx. 2 hours
Administration
Subcutaneous injection (laboratory models)
Research status
Preclinical / research use only
Calculate a dose

What it is

CJC-1295 is a growth-hormone-releasing hormone (GHRH) analogue; Ipamorelin is a selective ghrelin/GH secretagogue. Combined, they trigger pulsatile endogenous GH release without significantly elevating cortisol or prolactin.

Why researchers use it

  • Supports lean-mass and recovery research
  • Enhances sleep quality and recovery cycles
  • Mimics natural GH pulsatility rather than sustained elevation

Dosing protocol (for research)

Reconstitution (10 mg blended vial: 5 mg + 5 mg):

  • Reconstitute with 2 mL BAC water → 2.5 mg/mL of each
  • 0.10 mL (10 units) = 250 mcg CJC-1295 + 250 mcg Ipamorelin

Typical use: 100–300 mcg of each, most commonly at bedtime; some protocols split into 2–3 daily injections

Half-lives: CJC-1295 without DAC ~30 min; Ipamorelin ~2 hours

Preparation & injection

  • Store refrigerated after reconstitution
  • Subcutaneous injection, ideally before bed on an empty stomach for maximum GH pulse
  • Rotate injection sites

Safety notes

  • Occasional flushing, head-rush, or tingling shortly after injection
  • Water retention or mild appetite changes possible
  • Long-term suppression of endogenous GHRH is not well-characterized

Researcher tips

  • Bedtime dosing aligns with natural GH pulses
  • Avoid eating high-carb/high-fat meals 1–2 hours before injection to preserve pulse amplitude
  • Often stacked with recovery blends for post-training research protocols

Reconstitution & concentration

Per vial: 5 mg CJC-1295 + 5 mg Ipamorelin (10 mg total).

  • Reconstitute with 2 mL bacteriostatic water
  • Final concentration: 2.5 mg/mL of each compound
  • Each 0.1 mL (10 units) = 250 mcg CJC-1295 + 250 mcg Ipamorelin

Common protocols: 250–500 mcg of each, once or twice daily. Typical cycle: 8–12 weeks. SubQ, often pre-bedtime (to align with natural GH release) or post-workout.

Stacks

Researcher tips note CJC-1295 + Ipamorelin is often stacked with BPC-157 or TB-500 for recovery-focused protocols. It's advised against combining with excessive exogenous GH to avoid overstimulation.

Where to source